| Literature DB >> 29468052 |
Sheila de Benito1, Luis Alou2, Ricardo Becerro-de-Bengoa-Vallejo3, Marta Elena Losa-Iglesias1, María Luisa Gómez-Lus2, Luis Collado4, David Sevillano2.
Abstract
Background: This study aimed to estimate the prevalence of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) nasopharyngeal carriage among Doctors of Podiatric Medicine (Podiatrists) and to determine the potential risk factors.Entities:
Keywords: Methicillin; Nasal carriage; Podiatrists; Staphylococcus aureus; Staphylococcus epidermidis
Mesh:
Substances:
Year: 2018 PMID: 29468052 PMCID: PMC5816397 DOI: 10.1186/s13756-018-0318-0
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Results of the analysis of S. aureus and S. epidermidis carriers among podiatrists
| Variable | Category | N total (%) |
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MSSA | P | MRSA | P | MRSE | P | ||||||
| N | % | N | % | N | % | ||||||
| SEX | Female | 156 (65) | 30 | 19.2 | 2 | 1.2 | 29 | 8.6 | |||
| Male | 83 (35) | 25 | 30.1 | 0.0569 | 1 | 1.3 | 0.9593 | 28 | 33.7 | 0.0089 | |
| AGE | ≤35 | 157 (65.7) | 33 | 21.0 | 1 | 0.7 | 28 | 17.8 | |||
| 36 to 49 | 69 (28.9) | 17 | 24.6 | 2 | 3.9 | 24 | 34.7 | ||||
| ≥50 | 13 (5.4) | 5 | 38.5 | 0.3318 | 0 | 0.0 | 0.3408 | 5 | 38.5 | 0.0101 | |
| Years of Podiatry Experience | ≤ 5 | 80 (33.5) | 17 | 21.3 | 1 | 1.2 | 10 | 12.5 | |||
| 6 to 14 | 103 (43.1) | 21 | 20.3 | 1 | 1.0 | 25 | 24.2 | ||||
| ≥ 15 | 56 (23.4) | 17 | 29.8 | 0.3254 | 1 | 1.8 | 0.9074 | 22 | 39.3 | 0.0015 | |
| Use of a protection mask | Yes | 216 (90.4) | 51 | 23.6 | 3 | 1.4 | 53 | 24.5 | |||
| No | 23 (9.6) | 4 | 17.4 | 0.5005 | 0 | 0.0 | 0.5695 | 4 | 17.4 | 0.4446 | |
| Use of gloves | Yes | 237 (99.1) | 55 | 23.2 | 3 | 1.3 | 57 | 24.0 | |||
| No | 2 (0.8) | 0 | 0.0 | 0.4375 | 0 | 0.0 | 0.8728 | 0 | 0.0 | 0.4267 | |
| Use of an aspiration system | Yes | 171 (71.5) | 33 | 19.3 | 2 | 1.2 | 44 | 25.7 | |||
| No | 68 (28.5) | 22 | 32.3 | 0.0305 | 1 | 1.5 | 0.8504 | 13 | 19.1 | 0.2791 | |
| Concomitant disease | a | 187 (78) | 39 | 20.8 | 0.1330 | 3 | 1.6 | 0.3580 | 51 | 27.3 | 0.0185 |
| b | 0 (0.0) | 0 | 0.0 | ─ | 0 | 0.0 | ─ | 0 | 0.0 | ─ | |
| c | 38 (16) | 14 | 36.8 | 0.0272 | 0 | 0.0 | 0.4485 | 5 | 13.2 | 0.1795 | |
| d | 1 (0.4) | 0 | 0.0 | ─ | 0 | 0.0 | ─ | 0 | 0.0 | ─ | |
| e | 9 (3.7) | 2 | 22.2 | 0.9542 | 0 | 0.0 | 0.0870 | 1 | 11.0 | 0.3607 | |
| b,d | 2 (0.8) | 0 | 0.0 | ─ | 0 | 0.0 | ─ | 0 | 0.0 | ─ | |
| b,e | 1 (0.4) | 0 | 0.0 | ─ | 0 | 0.0 | ─ | 0 | 0.0 | ─ | |
| d,e | 1 (0.4) | 0 | 0.0 | ─ | 0 | 0.0 | ─ | 0 | 0.0 | ─ | |
ABREVIATIONS: (a) no disease; (b) diabetes; (c) respiratory disease; (d) immunosuppresive disease; (e) infectious disease
Antimicrobial susceptibility of isolated S. aureus strains
| Antibiotic | Number of strains | % | ||||
|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |
| RIFAMPICIN | 58 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| CHLORAMPHENICOL | 50 | 4 | 4 | 86.2 | 6.9 | 6.9 |
| LINEZOLID | 58 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| GENTAMICIN | 58 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| PENICILLIN | 9 | 0 | 49 | 15.5 | 0.0 | 84.5 |
| COTRIMOXAZOLE | 51 | 2 | 5 | 88.0 | 3.4 | 8.6 |
| CEFOXITIN | 55 | 0 | 3 | 94.8 | 0.0 | 5.2 |
| TETRACYCLINE | 58 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| VANCOMYCIN | 58 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| CIPROFLOXACIN | 54 | 4 | 0 | 93.1 | 6.9 | 0.0 |
| ERYTHROMYCIN | 45 | 0 | 13 | 77.6 | 0.0 | 22.4 |
| CLINDAMYCIN | 46 | 0 | 12 | 79.3 | 0.0 | 20.7 |
| MUPIROCIN | 51 | 0 | 7 | 88.0 | 0.0 | 12.0 |
ABBREVIATIONS: S susceptible, I intermediate susceptibility, R resistant
Antimicrobial susceptibility of isolated MRSE strains
| Antibiotic | Number of strains | % | ||||
|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |
| RIFAMPICIN | 55 | 0 | 2 | 96.5 | 0.0 | 3.5 |
| CHLORAMPHENICOL | 56 | 1 | 0 | 98.2 | 1.8 | 0.0 |
| LINEZOLID | 57 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| GENTAMICIN | 46 | 0 | 11 | 80.7 | 0.0 | 19.3 |
| PENICILLIN | 4 | 0 | 53 | 7.0 | 0.0 | 93.0 |
| COTRIMOXAZOLE | 44 | 0 | 13 | 77.2 | 0.0 | 22.8 |
| CEFOXITIN | 0 | 0 | 57 | 0.0 | 0.0 | 100.0 |
| TETRACYCLINE | 42 | 0 | 15 | 73.7 | 0.0 | 26.3 |
| VANCOMYCIN | 57 | 0 | 0 | 100.0 | 0.0 | 0.0 |
| CIPROFLOXACIN | 39 | 2 | 16 | 68.4 | 3.5 | 28.1 |
| ERITHROMYCIN | 12 | 0 | 45 | 21.1 | 0.0 | 78.9 |
| CLINDAMYCIN | 36 | 0 | 21 | 63.2 | 0.0 | 36.8 |
| MUPIROCIN | 15 | 0 | 42 | 26.3 | 0.0 | 73.7 |
ABBREVIATIONS: S susceptible, I intermediate susceptibility, R resistant
Number of antibiotics to which each strain was resistant
| Strain | Total N | Number of antibiotics to which the strains were resistant | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | ≥3 | ||||||
| N | % | N | % | N | % | N | % | ||
| MSSA | 55 | 7 | 12.7 | 28 | 50.9 | 9 | 16.4 | 11 | 20.0 |
| MRSA | 3 | 0 | 0.0 | 1 | 33.3 | 1 | 33.3 | 1 | 33.3 |
| MRSE | 57 | 0 | 0.0 | 0 | 0 | 4 | 7.0 | 53 | 93.0 |
ABBREVIATIONS: ATB antibiotic, 0 ATB resistant to zero antibiotics, 1 ATB resistant to one antibiotic, 2 ATB resistant to two antibiotics, ≥3 ATB resistant to three or more antibiotics